{
    "nct_id": "NCT06191744",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCOREâ„¢FL-2)",
    "inclusion_criteria": "* Diagnosis of follicular lymphoma (FL).\n* Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.\n* Are willing and able to comply with procedures required in the protocol.\n* Must have stage, II, III or IV disease.\n* Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.\n* Has one or more target lesions:\n\n  * A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and\n  * >=1 measurable nodal lesion (long axis >1.5cm) or >=1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].\n* Have laboratory values meeting the criteria in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Had major surgery within 4 weeks prior to randomization.\n* Have active cytomegalovirus (CMV) disease.",
    "miscellaneous_criteria": ""
}